Mycoplasma pneumoniae: Susceptibility and resistance to antibiotics

Future Microbiology

Volumn 6, Issue 4, 2011, Pages 423-431

  Bébéar, Cécile ^a,b   Pereyre, Sabine ^a,b   Peuchant, Olivia ^a,b  

^a Univ Victor Segalen Bordeaux 2   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

23S rRNA mutation; macrolide; macrolide resistance; Mycoplasma pneumoniae; respiratory tract infection

Indexed keywords

AZITHROMYCIN; CETHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CM 101; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; JOSAMYCIN; KETOLIDE; LEVOFLOXACIN; LINCOMYCIN; LINCOSAMIDE; MACROLIDE; MIDECAMYCIN; MINOCYCLINE; MOXIFLOXACIN; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PEFLOXACIN; PRISTINAMYCIN; ROXITHROMYCIN; SPIRAMYCIN; STREPTOGRAMIN; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CELL WALL; DRUG EFFICACY; DRUG POTENCY; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA GENITALIUM; MYCOPLASMA HOMINIS; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; UROGENITAL TRACT INFECTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA INFECTIONS; MYCOPLASMA PNEUMONIAE; RESPIRATORY TRACT INFECTIONS; RNA, RIBOSOMAL, 23S; TETRACYCLINES;

MYCOPLASMA; MYCOPLASMA PNEUMONIAE; MYCOPLASMATALES; SIA;

EID: 79955606245     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.11.18     Document Type: Review

References (50)

1. Waites KB, Balish MF, Atkinson TP: New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol. 3(6), 635-648 (2008).
2. Waites KB, Talkington DF: Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 17(4), 697-728 (2004). (Pubitemid 39372513)
3. Blanchard A, Bébéar CM: Mycoplasmas of humans. In:Molecular Biology and Pathogenicity of Mycoplasmas . Razin S, Herrmann R (Eds). Kluwer Academic/ Plenum Publishers, London, UK, 45-71 (2002).
4. Biscardi S, Lorrot M, Marc E et al.: Mycoplasma pneumoniae and asthma in children. Clin. Infect. Dis. 38(10), 1341-1346 (2004). (Pubitemid 38668576)
5. Sutherland ER, Brandorff JM, Martin RJ: Atypical bacterial pneumonia and asthma risk. J. Asthma 41(8), 863-868 (2004). (Pubitemid 40019138)
6. Bébéar CM, Pereyre S: Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr. Drug. Targets Infect. Disord. 5(3), 263-271 (2005). (Pubitemid 41448372)
7. Roberts MC: Antibiotic resistance. In:Mycoplasmas: Molecular Biology and Pathogenesis. Maniloff J, McElhaney RN, Finch LR, Baseman JB (Eds). American Society for Microbiology, Washington, DC, USA, 513-524 (1992).
8. Bébéar C: Mycoplasma, ureaplasma. In:Antibiogram . Courvalin P, Leclercq R, Rice LB (Eds). ESKA Publishing, ASM Press, Portland, USA, 519-529 (2010).
9. Bébéar CM, Kempf I: Antimicrobial therapy and antimicrobial resistance. In:Mycoplasmas: Pathogenesis, Molecular Biology, and Emerging Strategies for Control. Blanchard A, Browning GF (Eds). Horizon Bioscience Wymondham, UK, 535-568 (2005).
10. Gaurivaud P, Laigret F, Bové J-M: Insusceptibility of members of the class Mollicutes to rifampin: studies of the Spiroplasma citri RNA polymerase b-subunit gene. Antimicrob. Agents Chemother. 40(4), 858-862 (1996). (Pubitemid 26115216)
11. Bébéar CM, Renaudin H, Bryskier A, Bébéar C: Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob. Agents Chemother. 44(7), 1980-1982 (2000). (Pubitemid 30422960)
12. Kenny GE, Cartwright FD: Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines and fluoroquinolones. Antimicrob. Agents Chemother. 5(9), 2604-2608 (2001).
13. Pereyre S, Gonzalez P, de Barbeyrac B et al.: Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis. Antimicrob. Agents Chemother. 46(10), 3142-3150 (2002).
14. Waites KB, Crabb DA, Duffy LB: In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas. Antimicrob. Agents Chemother. 47(1), 39-42 (2003). (Pubitemid 36070339)
15. Waites KB, Crabb DM, Duffy LB: Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob. Agents Chemother. 53(5), 2139-2141 (2009).
16. Sainath Rao S, Raghunathan M: In vitro activity of the new quinolone derivative RD-3 against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis. J. Antimicrob. Chemother. 64(6), 1336-1368 (2009).
17. Pioletti M, Schlunzen F, Harms J et al.: Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO. J. 20(8), 1829-1839 (2001). (Pubitemid 32397386)
18. Chopra I, Roberts M: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65(2), 232-260 (2001). (Pubitemid 32538179)
19. Waites KB, Reddy NB, Crabb DM, Duffy LB: Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 49(6), 2541-2542 (2005). (Pubitemid 40734501)
20. Raherison S, Gonzalez P, Renaudin H, Charron A, Bébéar C, Bébéar CM: Evidence of an active efflux in resistance to ciprofloxacin and ethidium bromide by Mycoplasma hominis. Antimicrob. Agents Chemother. 46(3), 672-679 (2002). (Pubitemid 34157650)
21. Rocha EPC, Blanchard A: Genomic repeats, genome plasticity and the dynamics of Mycoplasma evolution. Nucleic Acids Res. 30(9), 2031-2042 (2002). (Pubitemid 34537601)
22. Oliver A, Canton R, Campo P, Baquero F, Blazquez J: High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288, 1251-1254 (2000).
23. Bradshaw CS, Jensen JS, Tabrizi SN et al.: Azithromycin failure in Mycoplasma genitalium urethritis. Emerg. Infect. Dis. 12(7), 1149-1152 (2006). (Pubitemid 44061291)
24. Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R: Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin. Infect. Dis. 47(12), 1546-1553 (2008).
25. Matsuoka M, Narita M, Okazaki N et al.: Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48(12), 4624-4630 (2004). (Pubitemid 39577663)
26. Okazaki N, Narita M, Yamada S et al.: Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol. Immunol. 45(8), 617-620 (2001). (Pubitemid 32785787)
27. Lucier TS, Heitzman K, Liu SK, Hu PC: Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 39(12), 2770-2773 (1995).
28. Pereyre S, Guyot C, Renaudin H, Charron A, Bébéar C, Bébéar CM: In vitro selection of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 48(2), 460-465 (2004). (Pubitemid 38141702)
29. Critchley IA, Jones ME, Heinze PD et al.: In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin. Microbiol. Infect. 8(4), 214-221 (2002). (Pubitemid 34993788)
30. Niitu Y, Hasegawa S, Suetake T, Kubota H, Komatsu S, Horikawa M: Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J. Pediatr. 76(3), 438-443 (1970).
31. Pereyre S, Charron A, Renaudin H, Bébéar C, Bébéar CM: First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J. Clin. Microbiol. 45(11), 3534-3539 (2007). (Pubitemid 350156844)
32. Stopler T, Gerichter CB, Branski D: Antibiotic-resistant mutants of Mycoplasma pneumoniae. Isr. J. Med. Sci. 16(3), 169-173 (1980). (Pubitemid 10094632)
33. Matsubara K, Morozumi M, Okada T et al.: A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J. Infect. Chemother. 15(6), 380-383 (2009).
34. Morozumi M, Iwata S, Hasegawa K et al.: Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 52(1), 348-350 (2008).
35. Morozumi T, Hasegawa K, Kobayashi R et al.: Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob. Agents Chemother. 49(6), 2302-2306 (2005). (Pubitemid 40734458)
36. Okazaki N, Ohya H, Sasaki T: Mycoplasma pneumoniae isolated from patients with respiratory infection in Kanagawa Prefecture in 1976-2006: emergence of macrolide-resistant strains. Jpn. J. Infect. Dis. 60(5), 325-326 (2007). (Pubitemid 47516887)
37. Morozumi M, Takahashi T, Ubukata K: Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J. Infect. Chemother. 16(2), 78-86 (2010).
38. Cao B, Zhao CJ, Yin YD et al.: High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin. Infect. Dis. 51(2), 189-194 (2010).
39. Liu Y, Ye X, Zhang H et al.: Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob. Agents Chemother. 53(5), 2160-2162 (2009).
40. Liu Y, Ye X, Zhang H et al.: Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn. Microbiol. Infect. Dis. 67(4), 355-358 (2010).
41. Xin D, Mi Z, Han X et al.: Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob. Agents Chemother. 53(5), 2158-2159 (2009).
42. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM: Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob. Agents Chemother. 52(10), 3542-3549 (2008).
43. Dumke R, von Baum H, Luck PC, Jacobs E: Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin. Microbiol. Infect. 16(6), 613-616 (2010).
44. Peuchant O, Menard A, Renaudin H et al.: Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J. Antimicrob. Chemother. 64(1), 52-58 (2009).
45. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB: Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr. Infect. Dis. J. 28(8), 693-696 (2009).
46. Spuesens EBM, Hoogenboezem T, Sluijter M, Hartwig NG, van Rossum AMC, Vink C: Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae by pyrosequencing. J. Microbiol. Methods 82, 214-222 (2010).
47. Dégrange S, Cazanave C, Charron A, Renaudin H, Bébéar C, Bébéar CM: development of multiple-locus variable-number tandem-repeat analysis for the molecular typing of Mycoplasma pneumoniae. J. Clin. Microbiol. 47(4), 914-923 (2009).
48. Suzuki S, Yamazaki T, Narita M et al.: Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 50(2), 709-712 (2006). (Pubitemid 43190986)
49. Gruson D, Pereyre S, Charron A, Renaudin H, Bébéar C, Bébéar CM: In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and in Mycoplasma hominis. Antimicrob. Agents Chemother. 49(3), 1190-1193 (2005). (Pubitemid 40327745)
50. Dégrange S, Renaudin H, Charron A, Pereyre S, Bébéar C, Bébéar CM: Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. J. Antimicrob. Chemother. 61(6), 1390-1392 (2008). (Pubitemid 351753613)